1. Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) managed with tafamidis showed decreased worsening in left ventricular (LV) systolic and diastolic function over 30 months compared to the placebo group. 2. Approximately half of the subjects enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) exhibited various levels of diminished left ventricular ejection fraction (LVEF),
1. In this randomized controlled trial, patisiran demonstrated a reduction in functional capacity decline transthyretin amyloidosis (ATTR amyloidosis) with a cardiac component as compared to placebo. 2. Compared to placebo, patisiran demonstrated a higher rate of infusion-related reactions, arthralgias, and muscle spasms. Evidence Rating Level: 1 (Excellent) Study Rundown: ATTR amyloidosis is a serious condition